Schonfeld Strategic Advisors LLC

Position in APGE — Apogee Therapeutics, Inc.

CIK 1665241 NEW YORK, NY

Back to APGE Full portfolio

Position in APGE

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$4,122,461

+$2,179,145 QoQ

Shares Held

31,059

+34.5% QoQ

Ownership

0.041%

of shares outstanding

% of Portfolio

0.03%

of 13F equity value

Holder Rank

#129

of 285 holders

Holding Since

Dec 2024

4 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Common Shares in APGE Over Time

Shares Held

Position Value (USD)

Derivatives in APGE

reported options exposure · as of Jun 30, 2026

CallValue

$663,650

CallShares

5,000

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Schonfeld Strategic Advisors LLC holds $420,669,608 across 133 Biotechnology names. APGE ranks #28 (1.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	INBX	Inhibrx Biosciences, Inc.	697,586	$66,096,273
2	AGIO	Agios Pharmaceuticals, Inc.	520,083	$19,300,280
3	JAZZ	Jazz Pharmaceuticals plc	77,272	$18,620,233
4	VRDN	Viridian Therapeutics, Inc.\DE	793,508	$14,576,741
5	MBX	MBX Biosciences, Inc.	248,670	$13,726,584
6	XENE	Xenon Pharmaceuticals Inc.	227,330	$13,721,638
7	PTCT	Ptc Therapeutics, Inc.	147,425	$12,025,457
8	INSM	INSMED Inc	104,378	$11,128,782

All Filings in APGE

Export CSV

5 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$663,650	5,000	—	Call	Sole	2026-08-14
2026-06-30	$4,122,461	31,059	+34.5%	Shares	Sole	2026-08-14
2026-03-31	$1,943,316	23,088	-20.8%	Shares	Sole	2026-05-15
2025-12-31	$2,199,864	29,145	-58.8%	Shares	Sole	2026-02-17
2024-12-31	$3,205,699	70,766	—	Shares	Sole	2025-02-14
No filing history on record for this holder in this stock.